BACKGROUND: The recent recommendation of the U.S. Preventive Services Task Force against PSA-based screening for prostate cancer was based, in part, on the lack of demonstrated diagnostic utility of serum PSA values in the low, but detectable range to successfully predict prostate cancer. Though controversial, this recommendation reinforced the critical need to develop, validate, and determine the utility of other serum and/or urine transcript and protein markers as diagnostic markers for PCa. The studies described here were intended to determine whether inflammatory cytokines might augment serum PSA as a diagnostic marker for prostate cancer. METHODS: Multiplex ELISA assays were performed to quantify CCL1, CCL2, CCL5, CCL8, CCL11, CCL17, CXCL1, CXCL5, CXCL8, CXCL10, CXCL12, and IL-6 protein levels in the serum of 272 men demonstrating serum PSA values of <10 ng/ml and undergoing a 12 core diagnostic needle biopsy for detection of prostate cancer. Logistic regression was used to identify the associations between specific chemokines and prostate cancer status adjusted for prostate volume, and baseline PSA. RESULTS: Serum levels for CCL1 (I-309) were significantly elevated among all men with enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated among men with prostate cancer regardless of prostate size (P < 0.01). The remaining 10 cytokines examined in this study did not exhibit significant correlations with either prostate volume or cancer status. CONCLUSIONS: Serum CCL11 values may provide a useful diagnostic tool to help distinguish between prostatic enlargement and prostate cancer among men demonstrating low, but detectable, serum PSA values.
BACKGROUND: The recent recommendation of the U.S. Preventive Services Task Force against PSA-based screening for prostate cancer was based, in part, on the lack of demonstrated diagnostic utility of serum PSA values in the low, but detectable range to successfully predict prostate cancer. Though controversial, this recommendation reinforced the critical need to develop, validate, and determine the utility of other serum and/or urine transcript and protein markers as diagnostic markers for PCa. The studies described here were intended to determine whether inflammatory cytokines might augment serum PSA as a diagnostic marker for prostate cancer. METHODS: Multiplex ELISA assays were performed to quantify CCL1, CCL2, CCL5, CCL8, CCL11, CCL17, CXCL1, CXCL5, CXCL8, CXCL10, CXCL12, and IL-6 protein levels in the serum of 272 men demonstrating serum PSA values of <10 ng/ml and undergoing a 12 core diagnostic needle biopsy for detection of prostate cancer. Logistic regression was used to identify the associations between specific chemokines and prostate cancer status adjusted for prostate volume, and baseline PSA. RESULTS: Serum levels for CCL1 (I-309) were significantly elevated among all men with enlarged prostates (P < 0.04). Serum levels for CCL11 (Eotaxin-1) were significantly elevated among men with prostate cancer regardless of prostate size (P < 0.01). The remaining 10 cytokines examined in this study did not exhibit significant correlations with either prostate volume or cancer status. CONCLUSIONS: Serum CCL11 values may provide a useful diagnostic tool to help distinguish between prostatic enlargement and prostate cancer among men demonstrating low, but detectable, serum PSA values.
Authors: M Uguccioni; C R Mackay; B Ochensberger; P Loetscher; S Rhis; G J LaRosa; P Rao; P D Ponath; M Baggiolini; C A Dahinden Journal: J Clin Invest Date: 1997-09-01 Impact factor: 14.808
Authors: G Theyer; G Kramer; I Assmann; E Sherwood; W Preinfalk; M Marberger; O Zechner; G E Steiner Journal: Lab Invest Date: 1992-01 Impact factor: 5.662
Authors: Marsha L Quick; Soumi Mukherjee; Charles N Rudick; Joseph D Done; Anthony J Schaeffer; Praveen Thumbikat Journal: Am J Physiol Regul Integr Comp Physiol Date: 2012-07-18 Impact factor: 3.619
Authors: E James Wright; Junyong Fang; E Jeffrey Metter; Alan W Partin; Patricia Landis; Daniel W Chan; H Ballentine Carter Journal: J Urol Date: 2002-06 Impact factor: 7.450
Authors: Georg E Steiner; Ursula Stix; Alessandra Handisurya; Martin Willheim; Andrea Haitel; Franz Reithmayr; Doris Paikl; Rupert C Ecker; Kristian Hrachowitz; Gero Kramer; Chung Lee; Michael Marberger Journal: Lab Invest Date: 2003-08 Impact factor: 5.662
Authors: Elena Farmaki; Vimala Kaza; Athanasios G Papavassiliou; Ioulia Chatzistamou; Hippokratis Kiaris Journal: Cancer Lett Date: 2016-12-29 Impact factor: 8.679
Authors: Milica Grozdanovic; Kimberly G Laffey; Hazem Abdelkarim; Ben Hitchinson; Anantha Harijith; Hyung-Geon Moon; Gye Young Park; Lee K Rousslang; Joanne C Masterson; Glenn T Furuta; Nadya I Tarasova; Vadim Gaponenko; Steven J Ackerman Journal: J Allergy Clin Immunol Date: 2018-05-17 Impact factor: 10.793
Authors: M R Milone; B Pucci; F Bruzzese; C Carbone; G Piro; S Costantini; F Capone; A Leone; E Di Gennaro; M Caraglia; A Budillon Journal: Cell Death Dis Date: 2013-05-23 Impact factor: 8.469